Should You Buy Eli Lilly Stock Before Oct. 30?

Eli Lilly is anticipated to report robust Q3 2025 results next week, with analysts projecting approximately $16 billion in revenue, a 40.5% year-over-year increase, and an average EPS of $5.92, significantly higher than the prior year, primarily fueled by strong sales of Mounjaro and Zepbound. Despite these strong growth expectations, the company's stock performance has not consistently correlated with earnings beats or misses in recent quarters, indicating that short-term market reactions may be influenced by factors beyond reported figures, such as 'whisper numbers' or earnings call commentary, making immediate post-earnings movements unpredictable.

Analysis

Eli Lilly is anticipated to report robust Q3 2025 results, with analysts projecting a 40.5% year-over-year revenue increase to approximately $16 billion. This follows strong Q2 2025 performance, where revenue jumped 38% and adjusted EPS soared 61%. Growth is primarily attributed to blockbuster drugs Mounjaro and Zepbound, which account for about 55% of total revenue.

Consensus EPS for Q3 2025 is $5.92, a substantial increase from $1.18 in Q3 2024, reflecting accelerating growth. However, EPS estimates show considerable dispersion, ranging from a pessimistic $5.49 to an optimistic $7.21 per share. This wide range suggests varying analyst confidence or differing models.

Despite strong fundamental expectations, Eli Lilly's stock performance has not consistently correlated with earnings beats or misses over the past four quarters. A 5.7% EPS miss in Q1 2025 led to a temporary stock rise, while a 12.9% beat in Q2 2025 saw an initial decline. This indicates factors beyond reported figures influence short-term reactions.

The inconsistent short-term stock behavior suggests immediate post-earnings movements are highly unpredictable, diverging from conventional market responses. This dynamic underscores the importance of long-term fundamental analysis over short-term trading strategies for LLY, given the company's strong core growth drivers.

Key Decisions for Investors

• Investors should prioritize a long-term perspective on Eli Lilly (LLY) given its strong fundamental growth drivers like Mounjaro and Zepbound, rather than attempting to time short-term earnings reactions.
• Monitor the Q3 2025 earnings call for management commentary and forward guidance, as these often influence market sentiment more than headline numbers.
• Be prepared for potential short-term volatility following the earnings release, as historical data shows inconsistent stock responses to beats or misses.